Rivaroxaban Initiation Protocol
For VTE treatment, initiate rivaroxaban at 15 mg twice daily with food for the first 21 days, then transition to 20 mg once daily with food for continued therapy. 1
Indication-Specific Dosing
Venous Thromboembolism (VTE) Treatment
- Initial phase (Days 1-21): 15 mg orally twice daily with food
- Maintenance phase (Day 22 onward): 20 mg orally once daily with food 1
This unique loading regimen for rivaroxaban distinguishes it from other DOACs and eliminates the need for parenteral anticoagulation bridging that is required with dabigatran or edoxaban 1.
Atrial Fibrillation (Stroke Prevention)
- Standard dose: 20 mg once daily with the evening meal 2
- Dose reduction: 15 mg once daily with the evening meal if CrCl 15-50 mL/min 2
The evening meal timing is critical for adequate absorption 2.
Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD)
- Dose: 2.5 mg twice daily (combined with aspirin 81-100 mg daily) 3
Critical Renal Dosing Adjustments
Renal function directly impacts rivaroxaban dosing due to 33% renal clearance 4:
- CrCl ≥50 mL/min: Standard dosing
- CrCl 30-49 mL/min: Use with caution; for AF indication, reduce to 15 mg daily 2
- CrCl 15-29 mL/min: For VTE, 10 mg once daily expected to achieve similar exposure to moderate renal impairment 3
- CrCl <15 mL/min: Avoid use 3
- Severe hepatic impairment (Child-Pugh B or C): Avoid use 3
Administration Requirements
Food significantly impacts absorption for higher doses:
- 15 mg and 20 mg doses must be taken with food 3
- 2.5 mg and 10 mg doses can be taken without regard to food 3
For patients unable to swallow tablets, rivaroxaban may be crushed and mixed with applesauce or suspended in water, but the 15 mg and 20 mg doses must still be immediately followed by food 3.
Transitioning From Other Anticoagulants
From LMWH to Rivaroxaban
Initiate rivaroxaban 22-28 hours after the last once-daily LMWH dose or 12-18 hours after the last twice-daily LMWH dose 5. This transition strategy has been validated as safe and well-tolerated in post-surgical patients 5.
From Warfarin to Rivaroxaban
Start rivaroxaban when INR <3.0 (for AF indication) or <2.0 (for VTE indication). No bridging required.
Special Clinical Scenarios
Post-Stroke in Atrial Fibrillation
For mild-moderate cardioembolic stroke (NIHSS <9), rivaroxaban can be safely initiated within 3-14 days of stroke onset 6. Evidence suggests initiation within 72 hours after successful reperfusion therapy does not increase hemorrhagic transformation risk, even when petechial hemorrhage is present on MRI 6.
Perioperative Management
Preoperatively:
- Low bleeding risk surgery: Hold 24 hours before procedure 7
- High bleeding risk surgery: Hold 48 hours before procedure 7
Postoperatively:
- Low bleeding risk: Resume 20 mg once daily 24 hours after surgery 7
- High bleeding risk: Resume 10 mg once daily for 2-3 days, then increase to 20 mg daily 7
Cancer-Associated VTE
Rivaroxaban is FDA-approved for cancer-associated VTE with the standard VTE dosing regimen (15 mg BID × 21 days, then 20 mg daily) 8. However, avoid in patients with gastric or gastroesophageal tumors due to increased major bleeding risk; prefer LMWH in this population 8.
Common Pitfalls to Avoid
Forgetting food requirement: The 15 mg and 20 mg doses have significantly reduced absorption without food—this is not optional 3
Incorrect VTE initiation: Starting at 20 mg daily from day 1 provides inadequate anticoagulation. The 15 mg BID loading phase for 21 days is essential 1
Inappropriate renal dosing: Unlike apixaban, rivaroxaban has substantial renal clearance (33%) requiring dose adjustment 4
Premature post-surgical resumption: After high-bleeding-risk surgery, jumping directly to full-dose therapy increases bleeding risk. Use the stepwise approach with reduced dosing initially 7
Timing with evening meal: For AF indication, specifically administer with the evening meal, not just any meal 2
Monitoring Considerations
No routine coagulation monitoring is required 9. However, rivaroxaban does affect PT/INR and anti-Xa levels if assessment of anticoagulation effect is needed clinically 3.